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Personalized Medicine in Heart Failure
Are We There Yet?*
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cAs we pursue the high bar of optimal quality of care
for patients with heart failure by targeting appro-
priate patients with all indicated evidence-based,
guideline-driven interventions, we are disquieted
not only by the cost implications but also by the
stark awareness that for some of our patients, many
of our therapies are likely minimally efficacious if
not frankly nonefficacious and all that is really
gained is exposure to harm. Remarkably, after
decades of investigation, we have no more specific
indication for evidence-based beta-blockers,
angiotensin-converting enzyme (ACE) inhibitors,
See page 409
or aldosterone antagonists than left ventricular ejec-
tion fraction measurements and New York Heart
Association classification—crude indicators at best
(1). And for the single indicated therapy with a
more precise descriptor of responsiveness, isosor-
bide dinitrate plus hydralazine for African-
American patients with heart failure, that treatment
has failed to experience any significant use for
indicated patients (2).
Differential responses to medical therapies as a
function of race, ethnicity, and sex, and possibly
similar differential response to device therapy as a
function of sex, have been well documented (3).
Certain genetic predilections may explain some of
this heterogeneity, but a more pragmatic answer
may be that the acquisition of the data suggesting
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relevant to the contents of this paper to disclose.ifferential responsiveness was flawed. Clearly race
nd/or ethnicity represent poor proxies for anything
hysiologic, and sex is only slightly better. A more
avorable scenario would be care that is guided by
uch more precise indications for therapy, clear
voidance of harm, and accurate predictors of re-
ponse. This is the promise of personalized medi-
ine—a promise that has not yet been delivered
espite this prolific era of biomarkers and an assort-
ent of “-omics.”
In this issue of iJACC, Dilsizian et al. (4) have
eported a novel strategy that identifies up-
egulation of myocardial ACE in laboratory animals
sing a targeted imaging agent, techentium-99m
abeled lisinopril (Tc-99m-Lis). Based on the ob-
ervation that myocellular ACE activity is up-
egulated in human and animal models of heart
ailure, the authors tested the feasibility of using
c-99m-Lis to distinguish the hearts of ACE-1
ver-expressing transgenic rats from those of wild-
ype control rats. Quantification of Tc-99m-Lis
ctivity in explanted hearts by gamma-well count-
ng demonstrated a nonsignificant increase of Tc-
9m-Lis uptake (expressed as percent injected dose
er gram) in transgenic versus control hearts at 10
in after injection (0.48  0.29% vs. 0.19 
.10%, p  0.171) and a significant increase in
c-99m-Lis uptake in transgenic versus control
earts at 30 min after injection (0.74  0.13% vs.
.17  0.03%, p  0.028). Pre-treatment with
nlabeled lisinopril substantially reduced Tc-99m-
is uptake, demonstrating specificity of the Tc-
9m-Lis radiotracer.
In vivo imaging was also performed utilizing a
mall-animal imaging system with combined
ingle-photon emission computed tomography and
omputed tomography capability (micro SPECT/
T). Three representative images acquired in vivo
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420were presented to highlight the potential of Tc-
99m-Lis as an imaging agent. Mirroring the ex vivo
data, the control rat demonstrated minimal myo-
cardial Tc-99m-Lis signal, the transgenic rat dem-
onstrated robust myocardial Tc-99m-Lis signal,
and pre-treatment of a transgenic rat with unlabeled
lisinopril resulted in minimal signal within the
myocardium and lungs.
Biochemical assays confirmed that ACE-1 en-
zyme activity was higher in transgenic animals
whereas control animals and animals pre-treated
with unlabeled lisinopril demonstrated the expected
low levels of ACE activity. The implication is that
those phenotypes with evidence of high tissue
ACE-1 activity would be especially good candidates
for ACE inhibition.
Do these data get us closer to personalized
medicine? Are we able to extrapolate that for
patients with heart failure in whom ACE activity
is up-regulated and maladapted, ACE inhibitor
therapy would be of greatest benefit? Older data
from a RAND Corporation meta-analysis of
available clinical trials suggested that women
receive no demonstrable benefit from ACE in-
hibitors (5). Similarly, post-hoc analyses from the
SOLVD (Studies of Left Ventricular Dysfunc-
tion) trials suggested that African Americans
respond less well to ACE inhibitors (6). With-
olding evidence-based therapies on the basis of
ex, race, or ethnicity is categorically untenable,
ut it is possible that not every woman or African
merican receiving an ACE inhibitor is deriving
benefit. A better approach is needed. Is an assess-
ent of ACE-1 activity the answer for ACE
nhibitor therapy?
The current data are certainly intriguing; how-
ver, several questions give us pause and demon-
trate how far we must go to acquire a precise
arker that will guide the use of evidence-based
herapy, in this case for heart failure. How accu-
ately does the over-expression of ACE-1 in trans-
enic animals correlate with up-regulated ACE-1
n clinical heart failure? The over-expression of
CE-1 in transgenic animals by 30-fold com-
ared to controls may not only be significantly
ifferent from human heart failure but may also
epresent the magnitude of difference required for
ccurate imaging. Would Tc-99m-Lis image a
esser level of increased ACE-1 activity with a
imilar degree of certainty? That large differences
n uptake can be appreciated by ex vivo quantifi-
ation is promising, but future studies will be
ecessary to define the accuracy with which invivo imaging can discriminate graded differences
in ACE activity. This task will be more difficult
in vivo, where high Tc-99m-Lis uptake in the
lungs (which was 50-fold higher than the heart
in this study) may compromise precise assessment
of myocardial ACE activity. Furthermore, trans-
lation of high-resolution small-animal micro
SPECT/CT findings to patients raises additional
challenges, such as reduced resolution and in-
creased soft tissue attenuation.
The activity of ACE-1 in heart failure cleaves
angiotensin I, yielding angiotensin II, and acts on
angiotensin 1-7 (Ang 1-7), a peptide that has
antithetical properties compared to angiotensin II
(7). Will Tc-99m-Lis imaging provide any insight
regarding ACE-1 activity on Ang 1-7? A well-
known variation of the ACE gene has a 287 base
pair Alu insertion in intron 16. The presence or
absence of this insertion yields 3 genotypes—II,
DD, and DI—of which the DD or dual deletion
genotype is associated with a greater cardiovascular
disease burden, especially hypertension. How will
Tc-99m-Lis imaging detect these genetic variations
of ACE?
The renin-angiotensin-aldosterone system is
complex. It is well documented that within weeks
after initiation of ACE inhibitor therapy, angioten-
sin II levels return to pre-treatment thresholds.
This verifies that generation of angiotensin II oc-
curs by non-ACE enzymatic activity. This obser-
vation almost assuredly dismisses chronic suppres-
sion of ACE-1 as the mechanism of clinical benefit
for ACE inhibitors. This and other candidate
mechanisms of action, for example, suppressing
kininase activity or increasing Ang 1-7 levels, may
remain quite important in determining clinical ben-
efit of ACE-I therapy even if upregulated tissue
ACE-1 activity per se is not the predominant
finding. Thus, how important is it to image ACE-1
activity in vivo?
The work done by Dilsizian et al. (4) is com-
mendable and represents a step closer to more
precise identification of phenotypes that may pre-
dict a better responsiveness to ACE-inhibitor ther-
apy. However, the focus of this field might merit a
more measured thought process. Perhaps the quest
here is not to identify the patients for whom the
response would be optimal but rather the patient for
whom either the risk would be great or the benefit
nil. Certainly, if the risk of angioedema due to an
ACE inhibitor, or hyperkalemia due to an aldoste-
rone antagonist, or bronchospasm due to a beta-
blocker could be predicted by assessment with a
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421radio-labeled tracer, then arguably it might be of
more clinical utility than another positive indication
for therapy.
Thus, meaningful research focused on increasing
our precision in the prescription of evidence-based
medical therapies for heart disease should continue.
But personalized medicine remains an unfulfilled
hope. For now, we should continue to advocate theacross subgroups in the African-American
3
4
5
gender, and diabetiheart failure per current indications for all appro-
priate patients.
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